The Academy supports full disclosure to physicians and patients of corporate ties and financial relationships between pharmaceutical manufacturers, mail order pharmacies, pharmacy benefit management (PBM) entities and pharmacists. Additionally, formulary decisions and “drug switching” should not be based principally on economic considerations, but on evidence-based therapeutic and quality of care considerations, to promote optimal patient care. (1998) (April 2015 BOD)
Share this page
Alert: Message field is required.
You must sign in before you can share a page on AAFP connection.
Disclosure of Corporate Ties Affecting Formulary Choices and Drug Substitution